Vanguard Group Inc. Grows Stock Holdings in Pulmonx Co. (NASDAQ:LUNG)

Vanguard Group Inc. lifted its position in shares of Pulmonx Co. (NASDAQ:LUNG) by 0.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,283,459 shares of the company’s stock after purchasing an additional 4,554 shares during the quarter. Vanguard Group Inc. owned 5.78% of Pulmonx worth $15,505,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Barclays PLC increased its holdings in Pulmonx by 1.8% in the 3rd quarter. Barclays PLC now owns 94,109 shares of the company’s stock worth $780,000 after acquiring an additional 1,679 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Pulmonx by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 315,532 shares of the company’s stock valued at $2,142,000 after buying an additional 2,363 shares during the period. Rhumbline Advisers lifted its holdings in shares of Pulmonx by 4.9% in the 4th quarter. Rhumbline Advisers now owns 53,503 shares of the company’s stock worth $363,000 after acquiring an additional 2,488 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Pulmonx by 8.8% in the fourth quarter. American Century Companies Inc. now owns 34,738 shares of the company’s stock valued at $236,000 after buying an additional 2,810 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Pulmonx by 27.0% during the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company’s stock worth $106,000 after purchasing an additional 3,310 shares in the last quarter. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on LUNG shares. D. Boral Capital started coverage on Pulmonx in a research report on Monday, March 10th. They issued a “buy” rating and a $17.00 price target on the stock. Morgan Stanley assumed coverage on shares of Pulmonx in a research note on Monday, March 10th. They set an “equal weight” rating for the company. Jefferies Financial Group initiated coverage on shares of Pulmonx in a research report on Monday, March 10th. They issued a “buy” rating on the stock. Finally, Citigroup started coverage on Pulmonx in a report on Monday, March 10th. They set a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Pulmonx has an average rating of “Moderate Buy” and a consensus price target of $12.75.

Insider Activity

In related news, insider Geoffrey Beran Rose sold 5,779 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.13, for a total transaction of $41,204.27. Following the transaction, the insider now directly owns 285,278 shares of the company’s stock, valued at approximately $2,034,032.14. The trade was a 1.99 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Mehul Joshi sold 14,384 shares of Pulmonx stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.12, for a total transaction of $102,414.08. Following the sale, the chief financial officer now directly owns 113,986 shares in the company, valued at $811,580.32. This trade represents a 11.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 145,660 shares of company stock valued at $1,128,484 in the last three months. Corporate insiders own 5.70% of the company’s stock.

Pulmonx Stock Performance

NASDAQ LUNG opened at $4.52 on Friday. The stock has a market cap of $181.92 million, a price-to-earnings ratio of -3.14 and a beta of 0.61. Pulmonx Co. has a fifty-two week low of $4.49 and a fifty-two week high of $10.01. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The business has a fifty day moving average of $7.07 and a 200-day moving average of $6.70.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. The firm had revenue of $23.77 million for the quarter, compared to analyst estimates of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. As a group, analysts predict that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.